A selection of highlights from @LancetGastroHep over the past 12 months - a mix of our most read, most discussed, and Editors' favourites 👉👉👉

#GITwitter #LiverTwitter For patients with NASH-related cirrhosis, 48 weeks of semaglutide did not improve liver fibrosis or result in resolution of NASH



@DrLoomba @ArunJSanyalVCU @schattenbergJ @phil_newsome7 #LiverTwitterthelancet.com/journals/langa…

Calvin Pan now presents on maternal TDF for prevention of vertical transmission in highly viraemic mothers #TLM22 clinicaltrials.gov/ct2/show/NCT03… 280 HBeAg+ mothers gestational age 12-13 weeks randomised 1:1 to early TDF from GW 14, or control group of TDF at GW 28. All infants got active immunoprophylaxis and HBIg only given to infants in the control group; 1ry endpoint HBV transmission at 28 weeks #TLM22

In part 2 of the #ALD #NASH SIG, Stephen Harrison covers #NASH therapeutics and MoAs #TLM22 @juanpabloarab now covers the therapy landscape for alcohol-associated hepatitis - steroids suboptimal with benefits beyond 1 month limited #TLM22

In the #NAFLD #ALD SIG, @stefano_romeo76 begins with a discussion of mechanisms of disease #TLM22 Some classic genetic stories, and some more recent ones… #TLM22

Giving the Thomas Starzl transplant state of the art lecture this year is Peter Friend, on normothermic transplantation — the ice box is now the rate limiting step, especially for extended criteria organs #TLM22 @OxTxResearch Published trials for benefits of normothermic perfusion devices accumulating, typically reduced acute liver injury, post-reperfusion syndrome, utilisation, and preservation time - but randomisation process in this setting introduces inherent selection biases #TLM22